QUICK SEARCH:   [advanced]
Author:
Keyword(s):
Year:  Vol:  Page: 

   

 

Health Affairs, 27, no. 5 (2008): w360-w370
(Published online 5 August 2008)
doi: 10.1377/hlthaff.27.5.w360
© 2008 by Project HOPE
 
New Online
 * Obama's Success & Next Steps
 * 3 Health Policy Options for President Obama
 * A Hybrid Proposal
 * Bipartisan Compromise
This Article
* Figures Only
* Full Text (HTML)
* Reprint (PDF)
* Appendix and Disclosures
* Submit a response to this article
* Comments: View responses
* Alert me when this article is cited
* Alert me when Comments are posted
* Alert me if a correction is posted
Services
* E-mail this article to a friend
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Personal Archive
* Download to Citation Manager
*Reprints & Permissions
Citing Articles
* Citing Articles via HighWire
Google Scholar
* Articles by Reed, S. D.
* Articles by Schulman, K. A.
PubMed
* PubMed Citation
* Articles by Reed, S. D.
* Articles by Schulman, K. A.
Related Collections
* Legal/Regulatory Issues
* Pharmaceuticals
* Research And Technology
* Consumer Issues

Web Exclusives

Use Of Larger Versus Smaller Drug-Safety Databases Before Regulatory Approval: The Trade-Offs

Shelby D. Reed, Kevin J. Anstrom, Damon M. Seils, Robert M. Califf and Kevin A. Schulman

Although efforts to revamp the drug-safety system have been directed at strengthening postmarketing surveillance, strategies for the preapproval stage may be useful. One strategy would be to require larger sample sizes in preapproval safety databases. To evaluate the potential benefits and costs of this approach, we developed a hypothetical model to estimate the expected incremental number of adverse drug events that could be avoided in a postapproval population. We found that the potential to limit adverse events can be an important consideration in sample-size determinations for preapproval trials. Requiring larger preapproval databases could be a cost-effective means of reducing adverse events in postapproval populations.


Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati    What's this?


This article has been cited by other articles:


Home page
Health Aff (Millwood)Home page
A. M. Garber
Is Having More Preapproval Data The Best Way To Assure Drug Safety?
Health Aff., September 1, 2008; 27(5): w371 - w373.
[Abstract] [Full Text] [PDF]

Comments:

Read all Comments

Hidden Costs To Increased Sample Size
Stephen A. Williams
Health Affairs, 19 Aug 2008 [Full text]


Home | Current Issue | Archives | Topic Collections | Search | Blog | Subscribe | Contact Us | Help

© 2001-2008 Project HOPE–The People-to-People Organization
Terms and Policies